Editorial Comment

References 

1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
   • CrossRef
2. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281
   • CrossRef
3. Miller AB, Hoogenstrataen B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
   • MEDLINE
   • CrossRef
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205–216
   • MEDLINE
   • CrossRef
5. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):22S–50S
6. Rosen MA, Schnall MD. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res. 2007;13:770s–776s
   • MEDLINE
   • CrossRef
7. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–1759
   • CrossRef
8. Cowey CL, Fielding JR, Rathmell WK. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response. J Urol. 2010;75:1108–1116
9. Van der Veldt AM, Meijerink MR, Alfons JM. Choi Response Criteria for Prediction of Clinical Outcome in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. Am Soc Clin Oncol. 2009;27:15s;Abstract 5044